Search results
Results from the WOW.Com Content Network
Tenosynovial giant cell tumor (TGCT) is a non-malignant tumor defined histologically as inclusions of “osteoclast-like” multinucleated giant cells, hemosiderin, and macrophages. [1] This histology can present one of 2 clinically distinct ways. TGCT tumors often develop from the lining of joints (also known as synovial tissue).
A number of tumors have giant cells, but are not true benign giant-cell tumors. These include, aneurysmal bone cyst, chondroblastoma, simple bone cyst, osteoid osteoma, osteoblastoma, osteosarcoma, giant-cell reparative granuloma, Giant-cell tumor of the tendon sheath and brown tumor of hyperparathyroidism. [citation needed]
Benign synovioma, or giant-cell tumor of the tendon sheath; Malignant synovioma, also known as: synovial sarcoma This page was last edited on 30 ...
Villonodular synovitis is a type of synovial swelling.. Types include: Pigmented villonodular synovitis; Giant cell tumor of the tendon sheath; Though they have very different names, they have the same histology, and stain positive for CD68, HAM56, and vimentin. [1]
Fibroma of tendon sheath is a benign tumor that presents as a small subcutaneous nodule that slowly increases in size. [1] This is a notably uncommon condition. According to case report literature, the tumors often have a multinodular growth pattern, with individual nodules being composed of bland, slender, spindle-shaped cells (myofibroblasts) in a dense, fibrous matrix.” [2] A common ...
A new House bill would ban health insurers from imposing arbitrary time limits on patients under anesthesia — days after Anthem Blue Cross Blue Shield only backed off the move amid outcry. “We ...
A giant cell (also known as a multinucleated giant cell, or multinucleate giant cell) is a mass formed by the union of several distinct cells (usually histiocytes), often forming a granuloma. [ 1 ] Although there is typically a focus on the pathological aspects of multinucleate giant cells (MGCs), they also play many important physiological roles.
From January 2008 to December 2012, if you bought shares in companies when Donald L. Nickles joined the board, and sold them when he left, you would have a -51.4 percent return on your investment, compared to a -2.8 percent return from the S&P 500.